Eloralintide

Eloralintide (LY3841136) is an investigational, long-acting peptide medication developed by Eli Lilly for obesity and related metabolic conditions. It is a selective amylin receptor agonist designed to preferentially activate the amylin-1 receptor (AMY1R). Amylin is a naturally occurring hormone released alongside insulin after eating that helps regulate appetite, satiety, and meal-related signaling. By stimulating this pathway, eloralintide is designed to help people feel full sooner, reduce food intake, and achieve sustained weight loss. Unlike GLP-1 medications such as semaglutide or dual GIP/GLP-1 medications such as tirzepatide, eloralintide primarily targets the amylin signaling system.

Human clinical trials have demonstrated meaningful weight reduction with once-weekly eloralintide, including up to 20.1% mean weight loss after 48 weeks in a Phase 2 study involving adults with obesity or overweight without type 2 diabetes. Eloralintide is also being investigated in combination with tirzepatide under the name EloraTZP. In a 48-week Phase 2b trial involving adults with obesity or overweight and type 2 diabetes, the highest-dose combination produced an estimated 23.3% mean weight reduction and a 2.9-percentage-point decline in HbA1c. These findings have led to Phase 3 clinical development. However, eloralintide and EloraTZP remain investigational, are not FDA-approved, and require additional research to establish long-term safety, optimal treatment regimens, and durable health outcomes.

Eloralintide works by mimicking selected actions of amylin, a hormone normally released by pancreatic beta cells alongside insulin after meals. Its primary therapeutic objective is to strengthen satiety signaling, helping regulate hunger, meal size, and calorie intake.

1. Selective Amylin-1 Receptor Activation

• Amylin receptors participate in communication between the brain, digestive system, and metabolic organs.
• Eloralintide is designed to preferentially activate the amylin-1 receptor (AMY1R).
• This selectivity distinguishes it from broader amylin and calcitonin receptor agonists.
• Preclinical research suggests limited activity at the calcitonin receptor relative to AMY1R.

2. Brainstem Satiety Signaling

• Amylin signaling involves brain regions that monitor nutritional status, including the area postrema and nucleus tractus solitarius.
• Activation of these pathways helps signal that sufficient food has been consumed.
• Eloralintide is intended to increase meal-related fullness and reduce subsequent food intake.
• The exact contributions of individual neural pathways in humans remain under investigation.

3. Appetite and Calorie Reduction

• Increased satiety can reduce the size and frequency of meals.
• Over time, lower energy intake can produce clinically meaningful weight reduction.
• Phase 2 trials demonstrated dose-related weight loss consistent with this mechanism.
• Eloralintide is not primarily a stimulant or direct fat-burning compound.

4. Gastric and Meal-Related Signaling

• Natural amylin participates in gastric emptying and postprandial glucose regulation.
• Amylin receptor activation may influence how rapidly food leaves the stomach.
• The magnitude and clinical importance of this effect specifically for eloralintide remain under investigation.

5. Glucose Regulation

• Natural amylin helps coordinate insulin, glucagon, and meal-related metabolic responses.
• In adults with type 2 diabetes, eloralintide monotherapy lowered HbA1c by approximately 1.1 to 1.4 percentage points in the 48-week Phase 2b trial.
• Greater HbA1c improvements occurred when eloralintide was combined with tirzepatide.

6. Complementary Signaling With Tirzepatide

• Tirzepatide activates GIP and GLP-1 receptors.
• Eloralintide primarily activates AMY1R.
• Combining the two molecules therefore targets three complementary hormonal pathways: amylin, GIP, and GLP-1.
• The combination is called EloraTZP and has demonstrated greater weight loss than either medicine alone in Phase 2 research.

7. Difference From Retatrutide

• Retatrutide is a single-molecule agonist targeting GIP, GLP-1, and glucagon receptors.
• EloraTZP uses two separate molecules to activate GIP, GLP-1, and amylin receptors.
• Although both approaches involve three hormone pathways, their third targets are different.
• These mechanisms should not be considered pharmacologically interchangeable.

The Key Difference: Eloralintide does not rely on direct GLP-1 receptor stimulation. Its distinct amylin pathway provides a potential alternative to incretin-based treatment and a complementary mechanism when combined with tirzepatide.

Researchers are interested in eloralintide because it offers an alternative biological pathway for weight management and has demonstrated substantial weight reduction in controlled human studies.

• Obesity Treatment: Phase 2 monotherapy studies demonstrated mean weight loss approaching 20% after 48 weeks.
• Appetite Regulation: Selective amylin receptor activation offers a mechanism distinct from GLP-1 and GIP signaling.
• Combination Therapy: Eloralintide has demonstrated additional weight-loss effects when combined with tirzepatide.
• Type 2 Diabetes: Clinical studies demonstrated improvements in HbA1c alongside weight loss.
• Incretin Treatment Add-On: Researchers are investigating whether eloralintide provides additional benefits for patients with persistent obesity while receiving incretin therapy.
• Obstructive Sleep Apnea: Phase 3 research is evaluating potential improvements in obesity-related sleep apnea.
• Knee Osteoarthritis: Ongoing trials are assessing obesity-related knee pain and function.
• Cardiometabolic Health: Studies have reported changes in waist circumference, blood pressure, lipids, and other risk factors.
• Treatment Individualization: A separate mechanism may eventually broaden therapeutic options for patients who do not respond adequately to existing medications.

Research Limitation: Although weight reduction is well demonstrated in Phase 2 trials, long-term cardiovascular outcomes, maintenance after discontinuation, and the effectiveness of eloralintide for sleep apnea or osteoarthritis have not yet been established.

Eloralintide has demonstrated clinically meaningful weight loss in randomized human studies. Its most advanced findings include a peer-reviewed 48-week Phase 2 monotherapy trial and announced 48-week Phase 2b results evaluating the combination with tirzepatide.

Eloralintide Monotherapy — Phase 2, Adults Without Type 2 Diabetes

EloraTZP — Phase 2b, Adults With Type 2 Diabetes

Notable Monotherapy Finding: The 48-week Phase 2 study enrolled 263 adults with obesity or overweight and at least one weight-related comorbidity, without type 2 diabetes. The 9 mg study arm achieved approximately 20.1% mean weight loss using the efficacy estimand.

Notable Combination Finding: The Phase 2b study enrolled 367 adults with obesity or overweight and type 2 diabetes. At the highest studied combination, mean weight reduction was 23.3%, compared with 14.8% in the tirzepatide 15 mg group.

High-Responder Finding: In the highest-dose combination group, approximately 63% of participants achieved at least 20% weight loss, while approximately 25% achieved at least 30% weight loss.

Additional Phase 1b Finding: A smaller study in adults without type 2 diabetes reported approximately 25.5% mean weight loss at 24 weeks in the high-dose eloralintide and tirzepatide combination arm. This early result should not be treated as equivalent to a large Phase 3 outcome.

Glycemic Control: The highest-dose EloraTZP combination reduced HbA1c by approximately 2.9 percentage points from an average starting HbA1c of 8.1%.

Tolerability Trade-Off: Discontinuation due to adverse events ranged from 10.8% to 27.0% across combination arms, compared with 2.9% in the tirzepatide 15 mg control arm.

Important Statistical Distinction: These reported percentages are efficacy-estimand results, estimating outcomes under continued treatment. They do not represent guaranteed real-world weight loss, and the combination data are currently based on Phase 2b conference and company disclosures.

Research Perspective: Eloralintide has demonstrated substantial effectiveness for weight reduction in Phase 2 research, while EloraTZP offers promising additional weight and glucose improvements. Larger Phase 3 trials are needed to establish long-term benefit, tolerability, and safety.

Eloralintide has been evaluated in human clinical trials using once-weekly subcutaneous administration. Unlike many research peptides, its studied doses come from controlled clinical trials. However, no FDA-approved dose, commercial formulation, or prescribing schedule exists for eloralintide itself or its combination with tirzepatide.

Published Clinical Dosing — Eloralintide Alone

Published Clinical Dosing — EloraTZP Combination

Clinical Trial Dose Escalation

• In the 48-week Phase 2b combination study, participants receiving eloralintide began at 1 mg or 3 mg and increased toward their assigned final study amount.
• Combination-arm participants receiving tirzepatide began at 2.5 mg and escalated according to the trial protocol, generally at four-week intervals.
• Target amounts were not necessarily administered from the first week of treatment.
• Researchers are investigating whether slower escalation can reduce gastrointestinal adverse effects while maintaining effectiveness.
• Future Phase 3 regimens may differ from the Phase 2 schedules.

Community-Reported Dosing

Unlike older research peptides, eloralintide is a recent pharmaceutical development with published human dose-ranging data. No independent, reliable community dosing standard or validated nonclinical protocol has been established. Online amounts copied from clinical trials should not be treated as instructions for using research-market preparations.

Administration Considerations:

• Route: Once-weekly subcutaneous injection in controlled clinical studies.
• Frequency: Weekly dosing was studied; alternate frequencies have not been clinically validated.
• Combination Formulation: The Phase 2b EloraTZP study used separate injections of eloralintide and tirzepatide.
• Future Co-Formulation: Lilly is advancing a single-injection combination formulation in Phase 3 development.
• Timing: No evidence establishes that morning, evening, or fasting administration is superior.
• Missed Doses: No FDA-approved missed-dose instructions exist for eloralintide.
• Reconstitution: No FDA-approved consumer preparation, validated universal mixing procedure, or home-storage schedule exists.
• Research Products: Product labels, vial concentrations, and vendor instructions do not establish equivalence to the pharmaceutical formulation used in clinical trials.

Important Distinction: The quantities above are studied clinical trial doses, not an approved or recommended treatment schedule. Eloralintide is still investigational, and combining it independently with tirzepatide is not equivalent to participating in Lilly's controlled combination studies.

Eloralintide is being developed as a long-term weight-management treatment rather than a peptide administered in brief experimental cycles. Published clinical research has evaluated treatment periods ranging from 12 to 48 weeks, with longer Phase 3 studies underway.

• Phase 1 Research: A multiple-dose trial evaluated approximately 12 weeks of once-weekly administration.
• Phase 2 Monotherapy: Evaluated treatment over 48 weeks in adults without type 2 diabetes.
• Phase 1b Combination Research: Smaller studies investigated eloralintide with tirzepatide over approximately 16–32 weeks.
• Phase 2b EloraTZP Research: Evaluated once-weekly combination treatment over 48 weeks.
• ENLIGHTEN Phase 3: Investigates longer-term monotherapy safety and effectiveness, including extended follow-up in selected populations.
• AMPLIFY Phase 3: Planned trials investigate the combined eloralintide and tirzepatide formulation over longer treatment periods.
• Maintenance Treatment: The optimal long-term maintenance regimen remains under investigation.
• Discontinuation: Weight regain, appetite changes, and durability of benefits after stopping eloralintide require further research.

Community Cycling: There is no scientific basis for assuming that short cycles, such as eight or twelve weeks on followed by a washout, provide the same weight-management benefits as continuous treatment in clinical trials.

Research Consideration: Obesity is a chronic condition, and clinical development is focused on sustained treatment. Long-term effectiveness, safety, and weight maintenance will need confirmation in the Phase 3 program.

Eloralintide is being studied as both a standalone amylin receptor agonist and a complementary treatment to incretin-based medications. The strongest combination evidence currently involves tirzepatide, which activates GIP and GLP-1 receptors.

Research Perspective: EloraTZP provides direct evidence that amylin and GIP/GLP-1 pathways can produce complementary weight-loss effects. However, this does not demonstrate that other experimental drug combinations are safe or effective.

Important Distinction: EloraTZP is not the same as retatrutide. EloraTZP involves amylin, GIP, and GLP-1 receptors, while retatrutide targets glucagon, GIP, and GLP-1 receptors.

Human clinical trials provide useful short- and medium-term safety information for eloralintide. The most frequently reported adverse effects involve the gastrointestinal system, appetite suppression, and fatigue. Side effects tend to be more frequent at higher study doses and during dose escalation, particularly when eloralintide is combined with tirzepatide.

Phase 1 Safety Finding: In a 12-week study involving 100 participants, decreased appetite was reported in 19% of participants receiving eloralintide, headache in 12%, fatigue in 11%, diarrhea in 10%, nausea in 8%, and vomiting in 4%.

Phase 2 Monotherapy Finding: Nausea and fatigue were the most frequently reported adverse effects. Slower dose escalation was associated with improved tolerability compared with some higher-dose approaches.

Phase 2b Combination Finding: Discontinuation because of adverse events ranged from 10.8% to 27.0% across EloraTZP combination arms. This compares with 2.9% for tirzepatide 15 mg alone in the same trial.

Additional Safety Context: Across the 367 treated participants in the Phase 2b study, 6.5% experienced at least one serious adverse event, and one death was recorded. These figures describe the overall trial population across treatment groups; they do not establish that eloralintide caused the serious events or death.

Important Clinical Consideration: Eloralintide combined with tirzepatide may produce stronger appetite suppression and weight loss, but the same combination can increase the burden of gastrointestinal adverse effects. Larger Phase 3 studies will help clarify the benefit-risk balance.

Research Perspective: Eloralintide has a developing clinical safety database and encouraging weight-loss efficacy, but it is not an approved medication, and its long-term safety profile remains incomplete.

Eloralintide does not yet have an FDA-approved prescribing label or formal contraindication list. Its clinical development program is still evaluating safety across people with obesity, type 2 diabetes, and related metabolic conditions.

• Pregnancy and Breastfeeding: Human pregnancy, fetal-development, and lactation safety data are insufficient.
• Severe Gastrointestinal Disorders: Individuals with significant nausea, vomiting, gastric-emptying disorders, or severe gastrointestinal disease may require particular caution.
• Pancreatitis History: Further safety evaluation is needed, particularly when eloralintide is combined with incretin medications.
• Gallbladder Disease: Significant weight loss and gastrointestinal symptoms can complicate preexisting gallbladder conditions.
• Dehydration / Kidney Disease: Persistent vomiting or diarrhea can lead to dehydration and potentially worsen kidney function.
• Type 2 Diabetes: Glucose-lowering effects require consideration when used with other diabetes treatments.
• Insulin / Sulfonylureas: Concurrent glucose-lowering medications may increase concern about hypoglycemia.
• History of Eating Disorders: Profound appetite suppression and rapid weight loss may create additional nutritional or behavioral concerns.
• Inadequate Protein Intake: Lower appetite may make it difficult to meet nutritional needs during substantial weight loss.
• Frailty / Low Muscle Mass: Preservation of functional lean tissue deserves particular attention during large weight reductions.
• Recent Serious Cardiovascular Events: Clinical trials commonly exclude certain patients with recent major cardiac events, limiting generalization to those populations.
• Prior Bariatric Surgery: Some Phase 3 studies exclude participants with prior or planned bariatric procedures.
• Concurrent Experimental Weight-Loss Compounds: Combining unapproved metabolic peptides introduces additional safety and tolerability uncertainty.
• Unregulated Products: Research-market preparations may not be equivalent to the investigational pharmaceutical product used in clinical studies.

Tirzepatide-Specific Warnings: When considering EloraTZP, the established safety warnings for tirzepatide also matter. These include its boxed warning about thyroid C-cell tumors in rodents and contraindications involving personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. These are tirzepatide labeling requirements and should not automatically be attributed to eloralintide monotherapy.

Regulatory Caution: Eloralintide and EloraTZP are not FDA-approved for obesity, diabetes, sleep apnea, or any other indication as of October 2026. Approved tirzepatide treatment is not the same as an approved eloralintide-tirzepatide combination.

Important Distinction: Phase 2 trials demonstrate meaningful weight loss, but larger clinical studies are still needed to establish long-term cardiovascular safety, treatment durability, and risks in medically complex populations.

Eloralintide clinical trials have primarily measured changes in body weight, metabolic health, glycemic control, and adverse events. Monitoring should distinguish treatment-related weight reduction from broader outcomes such as muscle preservation, cardiovascular health, nutritional adequacy, and long-term safety.

Body Composition Consideration: Large reductions in body weight can include decreases in both fat and lean mass. Changes in strength, functional performance, and body composition are important when interpreting treatment success.

Glycemic Research Consideration: In EloraTZP trials, HbA1c changes are particularly important because the combination influences three hormone systems associated with food intake and metabolic regulation.

Long-Term Safety Consideration: No laboratory panel or monitoring schedule independently establishes the safety of an investigational drug. Clinical monitoring protocols should follow the requirements of appropriately supervised research studies.